Specific acute myeloid leukemia oncogenic mutations that induce TIM-3 ligands confer susceptibility to anti–TIM-3 therapy, an intervention that reverses the T cell phenotype and metabolism. Here, HAVCR2 is linked to acute myeloid leukemia.